Near Normalisation of BG Improves the Potentiating Effect of GLP-1
Not Applicable
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Drug: glucagon-like peptide-1Drug: Saline
- Registration Number
- NCT00612625
- Lead Sponsor
- Hvidovre University Hospital
- Brief Summary
The ability of glucagon-like peptide 1 to enhance beta-cell responsiveness to I.v. glucose is impaired in patients with type 2 diabetes mellitus compared with healthy individuals. We investigated whether 4 weeks of near-normalisation og blood glucose improves the potentiation of glucose-stimulated insulin secretion by GLP-1
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
- Age 18-70 years
- Type 2 diabetes diagnosed after 30 years of age
- BMI > 25
Exclusion Criteria
- Severe complications to diabetes
- Abnormal liver og kidney function
- Haemoglobin below the lower limit
- Macroalbuminuria
- Systemic disease
- Pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description GLP-1 glucagon-like peptide-1 A graded glucose infusion with an infusion of GLP-1 (1½ pmol/kg/min) Saline Saline A graded glucose infusion together with a continuous infusion of saline
- Primary Outcome Measures
Name Time Method insulin secretion rate (ISR) were derived by deconvolution of c-peptide. ISR is expressed as pmol/kg/min 180 minutes
- Secondary Outcome Measures
Name Time Method The calculated ISR values was plotted against the ambient plasma glucose. The slopes of this linear relationships were calculated by cross-correlation analysis and is and estimation of beta-cell responsiveness (pmol/kg/min)/mmol/l 180 minutes
Trial Locations
- Locations (1)
Dept. of Endocrinology, Hvidovre Hospital
🇩🇰Copenhagen, Denmark